What does this research mean for the field?

Targeted quantification of donor-specific cell-free DNA provides a highly sensitive and noninvasive method for detecting and monitoring cardiac allograft rejection. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate whether targeted quantitative genotyping of circulating donor-specific cell-free DNA provides a rapid, cost-effective, and noninvasive method for detecting cardiac transplant rejection.

September 19, 2026Journal of the American College of CardiologyOpen Access

Highly Sensitive Noninvasive Cardiac Transplant Rejection Monitoring Using Targeted Quantification of Donor-Specific Cell-Free Deoxyribonucleic Acid

Q: What are the key findings of this study?

Targeted quantitative genotyping of DScf-DNA demonstrated 100% sensitivity and 84% specificity for detecting biopsy-proven rejection in pediatric heart transplant recipients.

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Pediatric cardiac transplant recipients (n=32). Intervention: Targeted quantitative genotyping of donor-specific cell-free DNA (DScf-DNA) vs. Endomyocardial biopsy (EMB). Primary outcome: Detection of biopsy-proven rejection (100% sensitivity and 84% specificity).

View Full Paper

Ask AI

Bookmark

Key result

DScf-DNA genotyping identifies pediatric heart transplant rejection with 100% sensitivity and 84% specificity.

100% sensitivity and 84% specificity
n=32

Why the study?

Does targeted quantitative genotyping of DScf-DNA accurately detect biopsy-proven rejection in pediatric cardiac transplant recipients?

Key Points

To evaluate whether targeted quantitative genotyping of circulating donor-specific cell-free DNA provides a rapid, cost-effective, and noninvasive method for detecting cardiac transplant rejection.
Measured the percentage of donor-specific cell-free DNA (DScf-DNA) in recipient plasma using targeted genotyping via Digital Analysis of Selected Regions (DANSR) and compared results to endomyocardial biopsies.
Circulating DScf-DNA >1% identified biopsy-proven rejection with 100% sensitivity and 84% specificity, whereas all samples with DScf-DNA <1% were negative for rejection (100% negative predictive value).
In 4 patients with active rejection, DScf-DNA levels fell significantly following intravenous immunosuppressive therapy and rebounded 3 to 4 days after discontinuing augmented immunosuppression in 3 patients.

Study Design

Type

Observational (n=32)

Blinding

blinded

Multicenter

Structured PICO

Does targeted quantitative genotyping of DScf-DNA accurately detect biopsy-proven rejection in pediatric cardiac transplant recipients?

Population

32 pediatric cardiac transplant recipients undergoing surveillance or diagnostic endomyocardial biopsy.

Exposure

Targeted quantitative genotyping of donor-specific cell-free DNA (DScf-DNA) from blood samples

Comparator

Catheter-based endomyocardial biopsy (EMB)

Outcome

Detection of biopsy-proven rejection (≥ ISHLT grade 2R or AMR1)surrogate

Main Result

Effect estimate: 100% sensitivity and 84% specificity

Limitations

Limited sample size
limited sample size

Authors

MHMats HidestrandChildren's Hospital of Wisconsin ATAoy Tomita‐MitchellMedical College of Wisconsin PHPip HidestrandLund University

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Targeted quantification of DScf-DNA offers a highly sensitive, non-invasive alternative to endomyocardial biopsy for monitoring cardiac transplant rejection in children.

Cite This Study

Hidestrand et al. (2013) conducted an observational in Pediatric cardiac transplant recipients (n=32). Targeted quantitative genotyping of donor-specific cell-free DNA (DScf-DNA) vs. Endomyocardial biopsy (EMB) was evaluated on Detection of biopsy-proven rejection (100% sensitivity and 84% specificity). Targeted quantitative genotyping of DScf-DNA demonstrated 100% sensitivity and 84% specificity for detecting biopsy-proven rejection in pediatric heart transplant recipients.

synapsesocial.com/papers/6aadfe74caa0b306db0bb28d https://doi.org/10.1016/j.jacc.2013.09.029

Topics

Heart transplantation

View Full Paper

Ask AI

Bookmark

Implication

Targeted quantification of DScf-DNA offers a highly sensitive, non-invasive alternative to endomyocardial biopsy for monitoring cardiac transplant rejection in children.

Highly Sensitive Noninvasive Cardiac Transplant Rejection Monitoring Using Targeted Quantification of Donor-Specific Cell-Free Deoxyribonucleic Acid

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Topics

Highly Sensitive Noninvasive Cardiac Transplant Rejection Monitoring Using Targeted Quantification of Donor-Specific Cell-Free Deoxyribonucleic Acid

Key Points

Study Design

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider